Breaking Genesis AI raises $500 million Series A at $3.5 billion valuation 3 sources · since 9:00 AM EST (42 min ago) · +1 more breaking
How it works

WhatsNewPaper

← Back to the front page

FDA declines to approve Summit lung cancer drug after survival miss

Summit said the FDA issued a complete response letter for ivonescimab in EGFR-mutated NSCLC after overall survival in HARMONi did not reach statistical significance.

What's new
  1. New headline Was: “US FDA declines to approve Summit lung cancer drug after trial misses key survival goal”
  2. Our desk filed its story